Claims for Patent: 9,925,158

Summary for Patent: 9,925,158

Title:	Enterically coated cysteamine, cystamine and derivatives thereof
Abstract:	The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
Inventor(s):	Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	15/656,903
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,925,158
Patent Claims:	1. A dosage form comprising enterically-coated granules having a core comprising cysteamine bitartrate and cystamine or a pharmaceutically-acceptable salt thereof; at least one pharmaceutically acceptable binder; and an enteric coating surrounding the core, wherein the enterically-coated granules release cysteamine and cystamine or a pharmaceutically-acceptable salt thereof at a pH of 4.5-6.5. 2. A method of treating a subject with cystinosis comprising administering a composition of claim 1 less than 4 times per day, wherein the total daily dose of cystamine is about 1.35 g/m.sup.2 body surface area or less. 3. A method of treating a subject with cystinosis comprising administering a composition of claim 1, wherein each administration comprises an amount of cysteamine bitartrate that would yield a dose of 100 to 1000 mg cysteamine free base. 4. A method of treating a subject with cystinosis comprising administering a composition of claim 1 less than 4 times per day in an amount to provide white blood-cell cystine suppression with a 12 hour level below 1 nmol/1/2cystine/mg protein. 5. A method of treating a subject with cystinosis comprising administering a composition of claim 1 twice per day in an amount to provide white blood-cell cystine suppression with a 12 hour level below 1 nmol/1/2cystine/mg protein. 6. A method of treating a subject with Huntington's Disease comprising administering the composition of claim 1, wherein each administration comprises an amount of cysteamine bitartrate that would yield a dose of 100 to 1000 mg cysteamine free base.